254 related articles for article (PubMed ID: 30072578)
1. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
Mol Cell Proteomics; 2018 Nov; 17(11):2132-2145. PubMed ID: 30072578
[TBL] [Abstract][Full Text] [Related]
2. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
Mol Cell Proteomics; 2019 Jun; 18(6):1255-1268. PubMed ID: 31154438
[TBL] [Abstract][Full Text] [Related]
3. Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse.
Rijensky NM; Blondheim Shraga NR; Barnea E; Peled N; Rosenbaum E; Popovtzer A; Stemmer SM; Livoff A; Shlapobersky M; Moskovits N; Perry D; Rubin E; Haviv I; Admon A
Mol Cell Proteomics; 2020 Aug; 19(8):1360-1374. PubMed ID: 32451349
[TBL] [Abstract][Full Text] [Related]
4. Soluble plasma HLA peptidome as a potential source for cancer biomarkers.
Bassani-Sternberg M; Barnea E; Beer I; Avivi I; Katz T; Admon A
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18769-76. PubMed ID: 20974924
[TBL] [Abstract][Full Text] [Related]
5. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
[TBL] [Abstract][Full Text] [Related]
6. Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.
Shraibman B; Kadosh DM; Barnea E; Admon A
Mol Cell Proteomics; 2016 Sep; 15(9):3058-70. PubMed ID: 27412690
[TBL] [Abstract][Full Text] [Related]
7. Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery.
Ritz D; Gloger A; Neri D; Fugmann T
Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27862975
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
9. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
10. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
[TBL] [Abstract][Full Text] [Related]
11. The nature and extent of contributions by defective ribosome products to the HLA peptidome.
Bourdetsky D; Schmelzer CE; Admon A
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1591-9. PubMed ID: 24715725
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.
Dutoit V; Herold-Mende C; Hilf N; Schoor O; Beckhove P; Bucher J; Dorsch K; Flohr S; Fritsche J; Lewandrowski P; Lohr J; Rammensee HG; Stevanovic S; Trautwein C; Vass V; Walter S; Walker PR; Weinschenk T; Singh-Jasuja H; Dietrich PY
Brain; 2012 Apr; 135(Pt 4):1042-54. PubMed ID: 22418738
[TBL] [Abstract][Full Text] [Related]
13. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.
Forlani G; Michaux J; Pak H; Huber F; Marie Joseph EL; Ramia E; Stevenson BJ; Linnebacher M; Accolla RS; Bassani-Sternberg M
Mol Cell Proteomics; 2021; 20():100032. PubMed ID: 33592498
[TBL] [Abstract][Full Text] [Related]
14. High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera.
Ritz D; Gloger A; Weide B; Garbe C; Neri D; Fugmann T
Proteomics; 2016 May; 16(10):1570-80. PubMed ID: 26992070
[TBL] [Abstract][Full Text] [Related]
15. Membranal and Blood-Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition.
Ritz D; Sani E; Debiec H; Ronco P; Neri D; Fugmann T
Proteomics; 2018 Jun; 18(12):e1700246. PubMed ID: 29314611
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients.
Kefayat A; Amouheidari A; Ghahremani F; Alirezaei Z
Cancer Med; 2021 Aug; 10(15):5154-5162. PubMed ID: 34250760
[TBL] [Abstract][Full Text] [Related]
17. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
18. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
Jarmalavicius S; Welte Y; Walden P
J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
[TBL] [Abstract][Full Text] [Related]
19. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma.
Zhou JX; Li Y; Chen SX; Deng AM
J Exp Clin Cancer Res; 2011 Jan; 30(1):2. PubMed ID: 21211023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
